0001193125-22-040944.txt : 20220214 0001193125-22-040944.hdr.sgml : 20220214 20220214132958 ACCESSION NUMBER: 0001193125-22-040944 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133529324 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-60069 FILM NUMBER: 22628845 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER COMPANY: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: DODGE & COX CENTRAL INDEX KEY: 0000200217 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 555 CALIFORNIA STREET STREET 2: 40TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 4159811710 MAIL ADDRESS: STREET 1: 555 CALIFORNIA STREET STREET 2: 40TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13G 1 d308063dsc13g.htm SC 13G SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 0)*

 

 

Sanofi

(Name of Issuer)

Ordinary Shares and American Depositary Shares

(Title of Class of Securities)

80105N105

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP NO. 80105N105   13G   PAGE 2 OF 4 PAGES

 

  1   

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Dodge & Cox    94-1441976

  2   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ☐        (b)  ☐

 

N/A

  3   

SEC USE ONLY

 

  4   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

California - U.S.A.

NUMBER OF

SHARES

 BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

       5     

SOLE VOTING POWER

 

24,109,804 Ordinary Shares and 88,784,333 American Depositary Shares

      6   

SHARED VOTING POWER

 

0

      7   

SOLE DISPOSITIVE POWER

 

24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

      8   

SHARED DISPOSITIVE POWER

 

0

  9   

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

10   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

N/A

11   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.6%

12  

TYPE OF REPORTING PERSON*

 

IA

 

Item 1(a)

Name of Issuer:

Sanofi

 

Item 1(b)

Address of Issuer’s Principal Executive Offices:

54 Rue La Boetie

Paris, France 75008

 

Item 2(a)

Name of Person Filing:

Dodge & Cox

 

Item 2(b)

Address of the Principal Office or, if none, Residence:

555 California Street, 40th Floor

San Francisco, CA 94104

 

Item 2(c)

Citizenship:

California - U.S.A.

 

Item 2(d)

Title of Class of Securities:

Ordinary Shares and American Depositary Shares

 

Item 2(e)

CUSIP Number:

80105N105

 

Item 3

If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

(e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

 

Item 4

Ownership:

 

  (a)

Amount Beneficially Owned:

24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

 

  (b)

Percent of Class:

5.6%

  (c)

Number of shares as to which such person has:

 

  (i)

sole power to vote or direct the vote:

24,109,804 Ordinary Shares and 88,784,333 American Depositary Shares

 

  (ii)

shared power to vote or direct the vote:

0

 

  (iii)

sole power to dispose or to direct the disposition of:

24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

 

  (iv)

shared power to dispose or to direct the disposition of:

0

 

Item 5

Ownership of Five Percent or Less of a Class:

Not applicable.

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Sanofi.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.

 

Item 8

Identification and Classification of Members of the Group:

Not applicable.

 

Item 9

Notice of Dissolution of a Group:

Not applicable.

 

Item 10

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2022                

 

DODGE & COX
By:  

/S/ Katherine M. Primas

Name:   Katherine M. Primas
Title:   Chief Compliance Officer